Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Aktis Oncology Inc.
Headquarters: Cambridge, MA, United States of America
Website: https://www.aktisoncology.com/...
Year Founded: 2021
Status: Private
See Emerging Company Profile .
BioCentury | Oct 3, 2024
Finance
Kurma investing new fund; Kailera advancing obesity assets with $400M
BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more
BioCentury | Jul 22, 2024
Product Development
Battle of the alphas: lead-212 picks up speed in radiopharma
The ɑ-emitting radioisotope’s rapid decay has logistical drawbacks, but its supply could beat actinium-225’s on scale
BioCentury | Jul 10, 2024
Management Tracks
Promotions for Flagship’s Afzelius, Biondi come amid $3.6B raise
Plus: EveryONE names CEO and chairman and updates from Lunit, Quell, ImCheck, Aktis, Immunic and Curve
BioCentury | Jul 1, 2024
Deals
Deals Report: Eisai regains ADC’s rights from BMS; Lilly’s latest radiopharma play
Plus: AbbVie buys Celsius; Fosun offers to take Henlius subsidiary private; Coherus divests biosimilar of Humira
BioCentury | May 29, 2024
Deals
Deals Report: Three $1B+ takeouts highlight demand in immunology, renal
Plus: Takeda-Degron to develop molecular glue degraders; Lilly-Aktis collaborate on radiopharmaceuticals; and more
BioCentury | Dec 5, 2023
Product Development
Dec. 4 Quick Takes: EyePoint’s data for Eylea competitor drive big gain
Plus: Seismic adds $121M in series B round and updates from Merck KGaA, Abbisko, Perpetual Medicines, CRISPR Therapeutics and YolTech
BioCentury | Dec 1, 2023
Product Development
Radiopharmaceuticals’ multi-dimensional next wave
Target, ligand and radioisotope choices fuel the growing field
BioCentury | Apr 20, 2023
Emerging Company Profile
Abdera: optimizing tunable radiotherapeutics for safety
Backed with $142M, start-up aims to thread a PK needle for antibody-based radiotherapies, avoiding kidney and bone marrow issues
BioCentury | Sep 20, 2022
Management Tracks
Luo joins Everest as CEO
Plus Hitchcock named CSO at Takeda, and updates from Viracta, Agios, Aktis and more
BioCentury | Aug 25, 2022
Deals
Aug. 25 Quick Takes: Radiopharma company Aktis tops off series A
Plus Takeda’s dengue vaccine gets first global approval, and updates from Pfizer, AstriVax, Ordaos, Zelluna and more
Items per page:
1 - 10 of 14